May 6th 2025
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Watch the series now!
Cancer Trial Participants Can Successfully Self-Report Adverse Events
Michigan Study Finds Obesity Lowers Hospice Use Among Seniors